GenScript establishes biology research collaboration with Roche
PISCATAWAY, N.J.—GenScript has signed a biology research collaboration with Roche Research & Development Center (RRDC) to provide assay development services for potential drug targets in line with Roche's drug development portfolio.
Recognizing the distinct advantages that CRO providers offer, many pharmaceutical companies have adapted an outsourcing strategy to increase productivity and offset costs.
GenScript is a contract research organization (CRO) focused in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization and antibody drug development.
"After the success of medicinal chemistry outsourcing, biology CRO is becoming a new trend in drug discovery. We expect a fruitful collaboration with GenScript in assay development," notes Dr. Li Chen, chief scientific officer of RRDC in China.
Dr. Frank Zhang, CEO of GenScript, points out that being the first drug discovery based R&D center established in China by a leading multinational pharmaceutical company, RRDC is taking the lead again in expanding into discovery biology arena.
"We appreciate the confidence that RRDC has shown in GenScript, and believe that the collaboration will mutually benefit us," he adds.